Kobo biotech Limited has submitted its quarterly compliance certificate to BSE Limited, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The filing relates to the quarter ended March 31, 2026, and was communicated to the stock exchange on April 15, 2026.

Regulatory Compliance Filing

The certificate was filed under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, which mandates quarterly compliance reporting by listed companies. IP Namrata Amol Randeri, serving as Resolution Professional for Kobo Biotech Limited, signed and submitted the compliance documentation to BSE Limited.

Registrar Confirmation

XL Softech Systems Ltd., acting as the company's Registrar and Share Transfer Agent, issued a confirmation certificate dated April 2, 2026. The registrar confirmed compliance with dematerialization requirements during the quarter ended March 31, 2026.

The RTA certification covers several key compliance areas:

• Securities received from depository participants for dematerialization were properly confirmed to depositories
• All securities comprised in certificates have been listed on the stock exchange
• Security certificates received for dematerialization were mutilated and cancelled after verification
• Depository names were substituted in the register of members within the required 30-day timeframe

Corporate Resolution Process

The filing indicates that Kobo Biotech Limited is currently under corporate insolvency resolution proceedings, with IP Namrata Amol Randeri serving as the Resolution Professional. The IBBI registration remains valid, and a dedicated email ID has been established for correspondence related to the resolution process.

The submission demonstrates the company's continued adherence to regulatory requirements despite being under resolution proceedings, ensuring transparency and compliance with SEBI guidelines for depositories and participants.

Kobo biotech Limited has formally communicated to BSE Limited regarding its status under SEBI's Large Corporate framework, confirming that it does not fall under the category of 'Large Corporate' as of March 31, 2026.

Regulatory Compliance Communication

The company's confirmation was made in reference to specific SEBI circulars governing fund raising through debt securities issuance by large entities. The communication specifically cited two key regulatory documents that establish the framework for Large Corporate classification.

SEBI Framework Adherence

The confirmation was made under Chapter XII of the SEBI Operational Circular, which provides applicability criteria for determining Large Corporate status. This classification is crucial for companies as it determines their obligations regarding debt securities issuance and related compliance requirements.

Corporate Resolution Process

The communication was signed by IP Namrata Amol Randeri, Resolution Professional, indicating that Kobo Biotech Limited is currently undergoing corporate insolvency resolution process. The Resolution Professional holds IBBI registration number IBBI/IPA-001/IP-P01585/2019-2020/12495, with AFA validity until December 31, 2025.

The company has requested BSE Limited to take this confirmation on record and acknowledge the same, ensuring compliance with regulatory requirements under the SEBI framework for Large Corporate classification.